Ulixacaltamide

Ulixacaltamide (Z944) is an orally available T-type calcium channel antagonist that can slow the progression of epilepsy. Ulixacaltamide effectively reduces tremor in a normal alkaline tremor animal model. Ulixacaltamide reverses thermal hyperalgesia and mediates pain relief[1][2][3][4].

Product Specifications

CAS Number

[1199236-64-0]

Product Name Alternative

Z944; PRAX-944

UNSPSC

12352005

Target

Calcium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ulixacaltamide.html

Concentration

10mM

Purity

98.73

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1=CC(F)=CC(Cl)=C1)NCC2CCN(CC2)CC(NC(C)(C)C)=O

Molecular Formula

C19H27ClFN3O2

Molecular Weight

383.89

References & Citations

[1]Marks WN, et al. The T-type calcium channel antagonist Z944 rescues impairments in crossmodal and visual recognition memory in Genetic Absence Epilepsy Rats from Strasbourg. Neurobiol Dis. 2016 Oct;94:106-15. |[2]Casillas-Espinosa P M, et al. Z944, a novel selective T-type calcium channel antagonist delays the progression of seizures in the amygdala kindling model[J]. PLoS One, 2015, 10 (8) : e0130012.|[3]Scott L, et al. Translational pharmacology of PRAX‐944, a novel T‐type calcium channel blocker in development for the treatment of essential tremor[J]. Movement Disorders, 2022, 37 (6) : 1193-1201.|[4]Antunes F T T, et al. Effect of ABT-639 on Cav3. 2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain[J]. European Journal of Pharmacology, 2024, 967: 176416.